Jul. 07, 2023

The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes with Benjamin Derman, MD

May. 31, 2023

Understanding More Sensitive Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD

Feb. 01, 2023

The New "Moda" in Multiple Myeloma: Modafakusp Alpha Targeting CD38 with Noa Biran, MD

Jan. 17, 2023

Myeloma Innovation in 2023 - An Annual Review

Nov. 14, 2022

The Approval of Teclistamab in Multiple Myeloma with Alfred Garfall, MD, UPENN

Oct. 31, 2022

Kidney Disease and Multiple Myeloma with Natalie Callander, MD, University of Wisconsin at Madison

Oct. 21, 2022

New Maintenance Strategies for Newly Diagnosed Myeloma Patients With Ashraf Badros, MD, University of Maryland

Jul. 18, 2022

A Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute

Jun. 27, 2022

Allo CAR T Myeloma Therapies with Jesus Berdeja, MD, Sarah Cannon Research Institute

Feb. 07, 2022

Looking Forward into 2022 in Multiple Myeloma With Robert Orlowski, MD, PHD, MD Anderson Cancer Center

Jan. 06, 2022

Engineered Toxin Bodies Targeting CD38 in Myeloma with Shaji Kumar, MD, Mayo Clinic

Jan. 05, 2022

Tasquinimod As a New Myeloma Therapy with Dan Vogl, MD and Yulia Nefedova, MD, PhD

Oct. 27, 2021

A Smoldering Myeloma Update with Elisabet Manasanch, MD, MD Anderson Cancer Center

Oct. 04, 2021

Managing Keratopathy for Patients on BLENREP with Cristina Gasparetto, MD and Mark Newman, OD

May. 18, 2021

Using Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma with Peter Voorhees, MD, Levine Cancer Institute

May. 14, 2021

Treating Amyloidosis with Sascha Tuchman, MD, University of North Carolina

Apr. 16, 2021

The New Abecma (ide-cel) CAR T FDA Approval in Multiple Myeloma with Dr. Noopur Raje, Mass General

Jan. 22, 2021

What's Coming in 2021 in Multiple Myeloma with Robert Orlowski, MD, PhD, MD Anderson Cancer Center